Join Growin Stock Community!

Oragenics, inc.OGEN.US Overview

US StockHealthcare
(No presentation for OGEN)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

OGEN AI Insights

OGEN Overall Performance

OGEN AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

OGEN Recent Performance

-3.08%

Oragenics, inc.

0.05%

Avg of Sector

-0.31%

S&P500

OGEN PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

OGEN Key Information

OGEN Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

OGEN Profile

Oragenics, Inc. develops antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus; and Terra CoV-2, an intramuscular vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement with Precigen, Inc. and ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.

Price of OGEN

OGEN FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

OGEN Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.62
PE Ratio (TTM)
0.02
Forward PE
-
PS Ratio (TTM)
89.28
PB Ratio
0.37
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-100.00%
Profit Growth (YoY)
-100.00%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.62
PE Ratio (TTM)
0.02
Forward PE
-
PS Ratio (TTM)
89.28
PB Ratio
0.37
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-100.00%
Profit Growth (YoY)
-100.00%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%

  • When is OGEN's latest earnings report released?

    The most recent financial report for Oragenics, inc. (OGEN) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating OGEN's short-term business performance and financial health. For the latest updates on OGEN's earnings releases, visit this page regularly.

  • How much cash does OGEN have?

    At the end of the period, Oragenics, inc. (OGEN) held Total Cash and Cash Equivalents of 11.4M, accounting for 0.9 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is OGEN's EPS continuing to grow?

    According to the past four quarterly reports, Oragenics, inc. (OGEN)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -1.96. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of OGEN?

    Oragenics, inc. (OGEN)'s Free Cash Flow (FCF) for the period is -2.98M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 51.48% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.